NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP
Twist Bioscience Corporation TWST
9 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$376.6M
▲ 20.3% vs FY2024
EPS · FY25
$-1.30
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-16.4%
Net margin · FY25
-20.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 376.6M
Revenue, FY2025 · full 9-year series below
Revenue
Net income
The company lost 21 cents on every revenue dollar this year.
Per share
USD -1.30
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-16.4%
Return on equity, FY2025
ROE
Operating margin-36.2%
Net margin-20.6%
Return on assets-12.4%
Each USD of equity lost 16 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+33.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+22.8%
+33.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.06B
Shares outstanding, FY2025
Change, 5 years+34.5%
Change, 10 years—
The share count grew 34% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 641.9M
total assets, end of FY2025
Total assetsUSD 641.9M
EquityUSD 473.0M
CashUSD 183.0M
Current ratio3.64×
Equity funds 74% of total assets.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
0.4
0.3
0.2
0.2
0.1
0.1
0.1
0.0
0.0
Operating income $B
−0.1
−0.2
−0.2
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
EBITDA $B
−0.1
−0.2
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
Income tax $B
0.0
0.0
0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
Net income $B
−0.1
−0.2
−0.2
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
EPS, diluted $
−1.30
−3.60
−3.60
−4.04
−3.15
−3.57
−3.92
−25.51
−24.49
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
−16.4
−38.1
−29.0
−31.8
−33.2
−57.3
·
·
·
Shares out B
0.06
0.06
0.06
0.06
0.05
0.05
0.03
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
25 of 25
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed